Relapsed or Refractory Diffuse Large B Cell Lymphoma Market, By Drug Type, By Distribution Channel, By Geography

Global relapsed or refractory diffuse large B cell lymphoma market is estimated to be valued at US$ 1,479.5 Mn in 2023 and is expected to exhibit a CAGR of 4.3% during the forecast period (2023-2030).

Figure 1. Global Relapsed or Refractory Diffuse Large B Cell Lymphoma Market Share (%), By Drug Type, 2023

Diffuse large B cell lymphoma (DLBCL) is the most common lymphoma that account forabout 25% to 30% of all non-Hodgkin lymphoma. This disease presents as a rapidly growing mass or enlarging lymph nodes in a nodal or extranodal site. Though aggressive, it does respond well to chemotherapy. It can affect many organ systems, and is best managed by an interprofessional team including the medical oncologist, radiation oncologist, and nephrologists. Radiation therapy can be needed in extranodal lymphomas. Kidney involvement has been well documented in patients with lymphoma. It is important to get the nephrologist involved early in the course of the disorder as renal failure is a complication of DLBCL itself, or renal failure can manifest during treatment. Careful assessment of the renal indices including acid-base, electrolytes, and volume status, should be assessed. The introduction of new drug with different technological platform and Mechanism of Action can contribute to market expansion. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period.

Market Dynamics

The key players in the pharmaceutical industry are focusing on development of platform based drug for relapsed or refractory diffuse large B cell lymphoma. Thus, introduction of such advanced products in the market is expected to drive growth of the global relapsed or refractory diffuse large B cell lymphoma market over the forecast period. For instance, on September 29, 2023, Regeneron Pharmaceuticals, Inc., a leading biotechnology company, announced that the U.S. Food and Drug Administration (FDA) had accepted for Priority Review the Biologics License Application (BLA) for odronextamab to treat adult patients with relapsed/refractory (R/R) follicular lymphoma (FL) or R/R diffuse large B-cell lymphoma (DLBCL), who have progressed after at least two prior systemic therapies. The target action date for the FDA decision is March 31, 2024. Odronextamab is an investigational CD20xCD3 bispecific antibody designed to bridge CD20 on cancer cells with CD3-expressing T cells to facilitate local T-cell activation and cancer-cell killing.

Key features of the study:

• This report provides an in-depth analysis of the global relapsed or refractory diffuse large B cell lymphoma market and provides market size (US$ Mn ) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global relapsed or refractory diffuse large B cell lymphoma market based on the following parameters- company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include MorphoSys U.S. Inc., Bristol Myers Squibb, Karyopharm Therapeutics, F.Hoffmann-La Roche AG, Merck & Co., Inc., Gilead Sciences, Inc., Novartis AG, Regeneron Pharmaceuticals, Cellular Biomedicine Group Inc., Genmab A/S, Incyte, AbbVie Inc., Janssen Biotech, Inc., Pfizer Inc., IMV Inc., Overland Pharmaceuticals (CY) Inc., ADC Therapeutics SA, Eagle Pharmaceuticals, Inc., and Adaptive Biotechnologies Corporation
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global relapsed or refractory diffuse large B cell lymphoma market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global relapsed or refractory diffuse large B cell lymphoma market

Detailed Segmentation:

• By Drug Type:
  • Monjuvi
  • XPOVIO
  • Polivy
  • Kymriah
  • Yescarta
  • Others
• By Distribution Channel:
  • Hospitals Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• By Region:
  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East
  • Africa
• Company Profiles
  • MorphoSys U.S. Inc.
  • Bristol-Myers Squibb Company
  • Karyopharm Therapeutics
  • F. Hoffmann-La Roche AG
  • Merck & Co., Inc.
  • Gilead Sciences, Inc.
  • Novartis AG
  • Regeneron Pharmaceuticals
  • Cellular Biomedicine Group Inc.
  • Genmab A/S
  • Incyte
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Pfizer Inc.
  • IMV Inc.
  • Overland Pharmaceuticals (CY) Inc.
  • ADC Therapeutics SA
  • Eagle Pharmaceuticals, Inc.
  • Adaptive Biotechnologies Corporation